Detalhe da pesquisa
1.
Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study.
Br J Cancer
; 129(12): 1940-1948, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37914801
2.
Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients. A TMRG and GINECO group study.
Gynecol Oncol
; 174: 190-199, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37210929
3.
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.
Lancet Oncol
; 23(8): 1044-1054, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35835135
4.
Cytoreductive Surgery and Intraperitoneal Chemotherapy in Advanced Serous Epithelial Ovarian Cancer: A 14-Year French Retrospective Single-Center Study of 124 Patients.
Ann Surg Oncol
; 29(5): 3322-3334, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-34994906
5.
Real-World Experience of Efficacy and Safety of Trabectedin in Patients with Soft Tissue Sarcoma: A Bicentric Retrospective Analysis.
Oncology
; 100(12): 633-644, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36283345
6.
A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study.
Gynecol Oncol
; 165(1): 30-39, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35123771
7.
Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).
Gynecol Oncol
; 164(1): 18-26, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34696892
8.
"Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors".
BMC Cancer
; 21(1): 1147, 2021 Oct 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34702204
9.
Renal dysfunction improves risk stratification and may call for a change in the management of intermediate- and high-risk acute pulmonary embolism: results from a multicenter cohort study with external validation.
Crit Care
; 25(1): 57, 2021 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33563311
10.
Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT).
Gynecol Oncol
; 159(1): 129-135, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32723678
11.
Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.
Lancet Oncol
; 20(1): 120-133, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30477937
12.
Non-pegylated liposomal doxorubicin (NPLD, Myocet®)â¯+â¯carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial.
Gynecol Oncol
; 152(1): 68-75, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30446275
13.
Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.
Gynecol Oncol
; 155(2): 262-269, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31604666
14.
Non-recommended dosing of direct oral anticoagulants in the treatment of acute pulmonary embolism is related to an increased rate of adverse events.
J Thromb Thrombolysis
; 46(3): 283-291, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-29869319
15.
Impact of Chemotherapy Beyond the Third Line in Patients With Recurrent Epithelial Ovarian Cancer.
Int J Gynecol Cancer
; 26(2): 261-7, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26807562
16.
Specific anticancer treatments in the last 3 months of life: a French experience.
Support Care Cancer
; 21(2): 405-12, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22736464
17.
Prise en charge des carcinomes ovariens de haut grade séreux et/ou endométrioïdes de stades avancés (III-IV) et testing HRD-BRCA en 2023 : actualisation selon les données publiées et/ou présentées en 2022.
Bull Cancer
; 110(6S): 6S5-6S9, 2023 Jun.
Artigo
em Francês
| MEDLINE | ID: mdl-37573039
18.
Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 20222023 : prise en charge du cancer de l'endomètre localisé.
Bull Cancer
; 110(6S): 6S20-6S33, 2023 Jun.
Artigo
em Francês
| MEDLINE | ID: mdl-37573036
19.
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.
Clin Cancer Res
; 29(20): 4068-4075, 2023 Oct 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37581616
20.
Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas.
Cancer
; 118(13): 3330-6, 2012 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22045619